Relationship Between Sarcopenia and Cardiovascular Diseases in the Elderly: An Overview
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
With the advent of population aging, aging-related diseases have become a challenge for governments worldwide. Sarcopenia has defined as a clinical syndrome associated with age-related loss such as skeletal muscle mass, strength, function, and physical performance. It is commonly seen in elderly patients with chronic diseases. Changes in lean mass are common critical determinants in the pathophysiology and progression of cardiovascular diseases (CVDs). Sarcopenia may be one of the most important causes of poor physical function and decreased cardiopulmonary function in elderly patients with CVDs. Sarcopenia may induce CVDs through common pathogenic pathways such as malnutrition, physical inactivity, insulin resistance, inflammation; these mechanisms interact. In this study, we aimed to investigate the relationship between sarcopenia and CVDs in the elderly. Further research is urgently needed to understand better the relationship, pathophysiology, clinical presentation, diagnostic criteria, and mechanisms of sarcopenia and CVDs, which may shed light on potential interventions to improve clinical outcomes and provide greater insight into the disorders above.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Sarcopenia: European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie, Y., Cederholm, T., Landi, F., Martin, F. C., Michel, J.-P., Rolland, Y., Schneider, S. M., et al. (2010) · Age and Ageing · doi:10.1093/ageing/afq034 · Cited by 11,601
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment
Chen, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Chou, M.-Y., Iijima, K., Jang, H. C., Kang, L., Kim, M., Kim, S., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.12.012 · Cited by 7,070
Sarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 1×
“In 2014 (8), the Asia Working Group for Sarcopenia (AWGS) and the Foundation for the National Institutes of Health (FNIH) also launched their respective expert consensus on sarcopenia.”
BackgroundOxidative stress, aging, and diseases
Liguori, I., Russo, G., Curcio, F., Bulli, G., Aran, L., Della-Morte, D., Gargiulo, G., Testa, G., Cacciatore, F., Bonaduce, D., et al. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s158513 · Cited by 3,979 · cited 2×
“The accumulation of ROS in the body will affect the nitrification, nitrosation, carbonylation, and glycation of proteins, thereby affecting muscle protein synthesis (77).”
BackgroundSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690 · cited 1×
“Senescenceassociated secretory phenotype (SASP) is one of the key factors in chronic inflammation-induced atherosclerotic plaque instability, part of the pathogenesis of atherosclerosis (63) and an independent risk factor for myocardial infarction”
BackgroundFielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P. M., McLean, R. R., Harris, T. B., Ferrucci, L., Guralnik, J. M., Fragala, M. S., Kenny, A. M., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glu010 · Cited by 2,545 · cited 2×
“EWGSOP (9), AWGs (10), IWGS (7), FNIH (12) all state that the diagnosis of sarcopenia should take into account a combination of muscle mass and muscle function, with the leading indicators including muscle mass, muscle strength, and muscle function.”
BackgroundSarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399
Cruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Kalinkovich, A., & Livshits, G. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2016.09.008 · Cited by 882 · cited 13×
“The SICA-HF study observed that in patients with HF, IL-6 was significantly higher in the sarcopenia group than in the non-sarcopenia group, but IL-1β and tumor necrosis factor-α did not differ significantly between the two groups (25, 70).”
BackgroundInfluentialSrikanthan, P., & Karlamangla, A. S. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0435 · Cited by 785
Nutritional recommendations for the management of sarcopenia
Morley, J. E., Argiles, J. M., Evans, W. J., Bhasin, S., Cella, D., Deutz, N. E. P., Doehner, W., Fearon, K. C. H., Ferrucci, L., Hellerstein, M. K., et al. (2010) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2010.04.014 · Cited by 664 · cited 1×
“Essential amino acids such as leucine and isoleucine are necessary to promote muscle protein synthesis (95, 96).”
BackgroundFulster, S., Tacke, M., Sandek, A., Ebner, N., Tschope, C., Doehner, W., Anker, S. D., & von Haehling, S. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs381 · Cited by 658
Ferrucci, L., Penninx, B. W. J. H., Volpato, S., Harris, T. B., Bandeen‐Roche, K., Balfour, J., Leveille, S. G., Fried, L. P., & Md, J. M. G. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50605.x · Cited by 618
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574 · cited 1×
“Sarcopenia often coexists with CVDs, tumors, chronic nonobstructive disease, chronic kidney disease, endocrine disease, and rheumatic immune disease (59).”
BackgroundCaminiti, G., Volterrani, M., Iellamo, F., Marazzi, G., Massaro, R., Miceli, M., Mammi, C., Piepoli, M., Fini, M., & Rosano, G. M. C. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.04.078 · Cited by 444
Nutrition and Sarcopenia—What Do We Know?
Ganapathy, A., & Nieves, J. W. (2020) · Nutrients · doi:10.3390/nu12061755 · Cited by 355 · cited 1×
“Rational Nutrition Nutritional intervention is currently the primary prevention and treatment method for sarcopenia, including supplementation of protein and amino acids (β-Hydroxy-β-Methyl butyrate (HMB), antioxidants, long-chain fatty acids, vitamin D, and creatine) (93, 94).”
MethodThe implications of sarcopenia and sarcopenic obesity on cardiometabolic disease
Kim, T. N., & Choi, K. M. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25077 · Cited by 225 · cited 1×
“Studies have shown that sarcopenia and obesity form a vicious circle in the body and then participate in the occurrence and development of CVDs led by CHD through a series of mechanisms such as insulin resistance, mitochondrial dysfunction, oxidative stress, adipokines, and inflammatory factors (58).”
BackgroundPharmacologic Options for the Treatment of Sarcopenia
Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225 · cited 1×
“Hormone Therapy Some studies have shown that supplementing testosterone is beneficial to muscle and skeletal tissues (108, 109), particularly in increasing muscle strength, improving mobility, and reducing the hospitalization rate of elderly patients with sarcopenia (110).”
BackgroundPolyzos, S. A., & Margioris, A. N. (2018) · Hormones · doi:10.1007/s42000-018-0049-x · Cited by 212
Senescent cells: a therapeutic target for cardiovascular disease
Childs, B. G., Li, H., & van Deursen, J. M. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95146 · Cited by 192
Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis
Stojanović, S. D., Fiedler, J., Bauersachs, J., Thum, T., & Sedding, D. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz919 · Cited by 188
Storer, T. W., Basaria, S., Traustadottir, T., Harman, S. M., Pencina, K., Li, Z., Travison, T. G., Miciek, R., Tsitouras, P., Hally, K., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2771 · Cited by 174 · cited 1×
“Decreased testosterone can cause fatigue and weakened exercise capacity, while testosterone supplementation can increase muscle strength and improve exercise capacity (111).”
BackgroundProtein and exercise in the prevention of sarcopenia and aging
Naseeb, M. A., & Volpe, S. L. (2017) · Nutrition Research · doi:10.1016/j.nutres.2017.01.001 · Cited by 160 · cited 1×
“Medium to longterm resistance training, aerobic exercise, and other forms of exercise or a mixture of exercise can significantly improve muscle strength, increase muscle mass, slow the progression of HF and inhibit skeletal muscle breakdown in some patients with sarcopenia (90).”
BackgroundBellanti, F., Romano, A. D., Lo Buglio, A., Castriotta, V., Guglielmi, G., Greco, A., Serviddio, G., & Vendemiale, G. (2018) · Maturitas · doi:10.1016/j.maturitas.2017.12.002 · Cited by 158 · cited 1×
“oxidative stress and are significantly associated with CVDs risk in such patients (78).”
BackgroundPhysical Exercise and Myokines: Relationships with Sarcopenia and Cardiovascular Complications
Barbalho, S. M., Flato, U. A. P., Tofano, R. J., Goulart, R. D. A., Guiguer, E. L., Detregiachi, C. R. P., Buchaim, D. V., Araújo, A. C., Buchaim, R. L., Reina, F. T. R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103607 · Cited by 156
Pulse wave velocity is associated with muscle mass decline: Health ABC study
study, F. T. H. A., Abbatecola, A. M., Chiodini, P., Gallo, C., Lakatta, E., Sutton-Tyrrell, K., Tylavsky, F. A., Goodpaster, B., de Rekeneire, N., Schwartz, A. V., et al. (2012) · AGE · doi:10.1007/s11357-011-9238-0 · Cited by 114
Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease
Uchida, S., Kamiya, K., Hamazaki, N., Matsuzawa, R., Nozaki, K., Ichikawa, T., Suzuki, Y., Nakamura, T., Yamashita, M., Kariya, H., et al. (2020) · Heart and Vessels · doi:10.1007/s00380-020-01554-8 · Cited by 52 · cited 1×
“In contrast, the grip strength does not correlate with it (46).”
BackgroundArazi, H., Taati, B., & Suzuki, K. (2018) · Antioxidants · doi:10.3390/antiox7100148 · Cited by 40
Arazi, H., Taati, B., & Suzuki, K. (2021) · Recent Research Advances in Biology Vol. 5 · doi:10.9734/bpi/rrab/v5/7486d · Cited by 6
Cited by
Sarcopenia and Cardiovascular Diseases
Damluji, A. A., Alfaraidhy, M., AlHajri, N., Rohant, N. N., Kumar, M., Al Malouf, C., Bahrainy, S., Ji Kwak, M., Batchelor, W. B., Forman, D. E., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.064071 · Cited by 645
Chronological vs Biological Age in Interventional Cardiology
Damluji, A. A., Nanna, M. G., Rymer, J., Kochar, A., Lowenstern, A., Baron, S. J., Narins, C. R., & Alkhouli, M. (2024) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2024.01.284 · Cited by 53
Morikawa, M., Lee, S., Makino, K., Harada, K., Katayama, O., Tomida, K., Yamaguchi, R., Nishijima, C., Fujii, K., Misu, Y., et al. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.03.008 · Cited by 41
Metadata
- Authors
- He, N., Zhang, Y., Zhang, L., Zhang, S., & Ye, H.
- Venue
- Frontiers in Cardiovascular Medicine
- Publisher
- Frontiers Media SA
- Published
- 2021-12-09
- Volume
- 8
- Pages
- 743710-743710
- ISSN
- 2297-055X (ISSN-L)
- OpenAlex
- W4200446953
- Cited by
- 157
- References
- 32
- FWCI
- 10.97
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.